School of Regenerative Medicine, Manipal Academy of Higher Education, Yelahanka, Bangalore-560065, India.
Dept. of Physiology, Melaka Manipal Medical College, Manipal Academy of Higher Education, Manipal, India.
Curr Gene Ther. 2017;17(5):379-390. doi: 10.2174/1566523218666180125091952.
BACKGROUND: Neurodegenerative diseases comprise a group of disorders for which no treatment is available till date. Stem cell based therapy offers great hope and promise. However, stem cell transplantation is associated with certain disadvantages like poor targeted migration, engraftment and survival of the transplanted cells. MATERIAL & METHOD: Exosomes, a type of extracellular membrane vesicle released by all cell types including stem cells, offer an alternative to stem cell transplantation. Exosome carry a wide array of biomolecules and are implicated in exhibiting substantial benefits in the repair/regeneration of the injured tissue. Thus, exosomes offer an alternative therapeutic approach as a substitute of cell transplantation. In order to utilize exosomes for therapeutic purpose, it is essential to evaluate the appropriate passage number and the dosage to avoid possible cytotoxic effects. Here, we isolated exosomes from different passages of rat bone marrow mesenchymal stem cells (BM-MSC) and analysed the neuroprotective potential of BM-MSC exosomes in an in vitro model of excitotoxicity. RESULT: Our results demonstrated that the exosomes isolated from early passage of rat BM-MSC exhibited more efficient neuroprotective potential as opposed to later passages derived exosomes. Furthermore, the neuroprotective efficacy of exosome is dosage dependent. i.e. the lower dosage of exosomes was found to be neuroprotective, whereas higher dosage of exosomes (from later passages) was found to be detrimental to neurons. The early passage derived exosomes protected neurons through anti-apoptotic, anti-necrotic and anti-oxidant mechanisms. CONCLUSION: Our study suggests that adult stem cells derived exosomes could be a potential therapeutic agent to confer neuroprotection in neurodegenerative diseases like Alzheimer's disease.
背景:神经退行性疾病包括一组目前尚无治疗方法的疾病。基于干细胞的治疗方法提供了巨大的希望和承诺。然而,干细胞移植存在一些缺点,例如移植细胞的靶向迁移、植入和存活能力差。
材料与方法:外泌体是一种由所有细胞类型(包括干细胞)释放的细胞外膜囊泡,为干细胞移植提供了一种替代方法。外泌体携带广泛的生物分子,并被认为在受损组织的修复/再生方面具有显著益处。因此,外泌体提供了一种替代的治疗方法,可以替代细胞移植。为了将外泌体用于治疗目的,必须评估适当的传代数和剂量,以避免可能的细胞毒性作用。在这里,我们从大鼠骨髓间充质干细胞(BM-MSC)的不同传代中分离出外泌体,并在体外兴奋毒性模型中分析 BM-MSC 外泌体的神经保护潜力。
结果:我们的结果表明,与来自后期传代的外泌体相比,从大鼠 BM-MSC 早期传代中分离的外泌体表现出更有效的神经保护潜力。此外,外泌体的神经保护效果与剂量有关。即,较低剂量的外泌体被发现具有神经保护作用,而较高剂量的外泌体(来自后期传代)则对神经元有害。早期传代衍生的外泌体通过抗凋亡、抗坏死和抗氧化机制保护神经元。
结论:我们的研究表明,成体干细胞衍生的外泌体可能是一种有潜力的治疗剂,可以在阿尔茨海默病等神经退行性疾病中提供神经保护。
J Thorac Cardiovasc Surg. 2018-8-20
J Extracell Biol. 2025-8-20
Burns Trauma. 2025-1-23
Genes Dis. 2023-9-19
J Extracell Biol. 2023-10-16
Neuroprotection. 2023-12
Int J Mol Sci. 2023-11-20